The virtuous cycle of human genetics and mouse models in drug discovery

被引:0
|
作者
Joseph H. Nadeau
Johan Auwerx
机构
[1] Pacific Northwest Research Institute,
[2] Laboratory of Integrative and Systems Physiology,undefined
[3] Interfaculty Institute of Bioengineering,undefined
[4] École Polytechnique Fédérale de Lausanne,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Ongoing studies in many species seek to understand the origins, architecture and consequences of phenotypic variation under normal and dysfunctional conditions, with the aim of identifying targets for intervention that can prevent, stabilize or reverse disease. Some suggest that only humans are appropriate for studying these questions and argue that candidate drug targets identified in mouse models are largely unreliable. Here, we review the vast evidence showing that mouse models continue to make fundamental contributions to our understanding of genetic principles, pathogenic mechanisms and therapeutic modalities. We propose a virtuous cycle in which the power of observational studies and natural experiments in humans are closely integrated with the rigour of true experiments in model organisms.
引用
收藏
页码:255 / 272
页数:17
相关论文
共 50 条
  • [41] Understanding CLL biology through mouse models of human genetics
    ten Hacken, Elisa
    Wu, Catherine J.
    BLOOD, 2021, 138 (25) : 2621 - 2631
  • [42] Migraine pathophysiology: lessons from mouse models and human genetics
    Ferrari, Michel D.
    Klever, Roselin R.
    Terwindt, Gisela M.
    Ayata, Cenk
    van den Maagdenberg, Arn M. J. M.
    LANCET NEUROLOGY, 2015, 14 (01): : 65 - 80
  • [43] Genetics of complex disorders and drug discovery
    Middleton, L
    JOURNAL OF MEDICAL GENETICS, 2003, 40 : S13 - S13
  • [44] Systems genetics for drug target discovery
    Penrod, Nadia M.
    Cowper-Sal-Iari, Richard
    Moore, Jason H.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (10) : 623 - 630
  • [45] Cancer genetics and drug discovery in the zebrafish
    Howard M. Stern
    Leonard I. Zon
    Nature Reviews Cancer, 2003, 3 : 533 - 539
  • [46] Application of Bayesian approaches in drug development: starting a virtuous cycle
    Ruberg, Stephen J. J.
    Beckers, Francois
    Hemmings, Rob
    Honig, Peter
    Irony, Telba
    LaVange, Lisa
    Lieberman, Grazyna
    Mayne, James
    Moscicki, Richard
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (03) : 235 - 250
  • [47] Reply to 'Bayesian approaches in drug development: continuing the virtuous cycle'
    Ruberg, Stephen J.
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (12) : 964 - 964
  • [48] Orthotopic mouse models expressing fluorescent proteins for cancer drug discovery
    Hoffman, Robert M.
    EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (09) : 851 - 866
  • [49] Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
    Playa-Albinyana, Heribert
    Arenas, Fabian
    Colomer, Dolors
    EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (10) : 1085 - 1090
  • [50] Mouse models in squamous cell lung cancer: impact for drug discovery
    Singh, Aditi P.
    Herrera, Diego Adrianzen
    Zhang, Yifei
    Perez-Soler, Roman
    Cheng, Haiying
    EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (04) : 347 - 358